BiotechTubeBiotechTube
Home/Pipeline/CVx1

CVx1

Muscle-Invasive Bladder Cancer

Phase 1/2Active (GMP production & trial preparation)

Key Facts

Indication
Muscle-Invasive Bladder Cancer
Phase
Phase 1/2
Status
Active (GMP production & trial preparation)
Company
CimCure, CimCure

About CimCure

CimCure, a 2016 spin-off from Amsterdam UMC, is pioneering an anti-angiogenic immunotherapy approach to cancer. The company's core iBoost technology fuses a foreign protein to a tumor-specific endothelial protein, triggering a potent antibody response that destroys the tumor vasculature. Having secured seed investment and an innovation credit, CimCure is advancing its lead vaccine CVx1 into clinical trials, aiming for a broadly applicable treatment for solid tumors.

View full company profile

About CimCure

CimCure, a 2016 spin-off from Amsterdam UMC, is pioneering an anti-angiogenic immunotherapy approach to cancer. The company's core iBoost technology fuses a foreign protein to a tumor-specific endothelial protein, triggering a potent antibody response that destroys the tumor vasculature. Having secured seed investment and an innovation credit, CimCure is advancing its lead vaccine CVx1 into clinical trials, aiming for a broadly applicable treatment for solid tumors.

View full company profile

Therapeutic Areas

Oncology